ACT China III 2013

 

In 2013, the first Biomarkers Satellite Workshop was held prior to ACT China III by invitation only. Experts explored what is needed to deploy a nationwide testing of tumors for those molecular abnormalities that are likely to impact patient care. This Satellite Workshop brings together clinical oncologists, biomarker assay experts, and representatives of the CFDA of China, the FDA of the United States and Europe's EMA, to develop a plan for standardized cancer biomarker testing in China – for both clinical trials and for patient care.

[View Biomarkers Program]

Over the course of the 3-day ACT China III Workshop, a global faculty of experts addressed the current issues and challenges in carrying out Phase I, II and III clinical trials through a series of lectures, discussions, and workshops. We believe that the curriculum – covering ethics, preclinical studies, clinical trial design and conduct, statistics and regulatory considerations – will help transform oncology research in China for the benefit of cancer patients in China and around the world.

[View ACT China III Program]

Platinum Level/Founding Charter Sponsor: Sanofi Gold Level Sponsor: Shanghai Roche Pharmaceuticals Jade Level Sponsor: Bayer Healthcare Pharmaceuticals Pearl Level Sponsor: BTG International Canada, Quintiles In-Kind Support: ASCO, Conquer Cancer Foundation, AlphaMed Press

The videos below are in Chinese. To watch the same videos in English, please click here.
点击此处播放英文版演讲视频。

Chromeless Video Player with Tabbed Playlists attached to Chinese playlist.